CSL Limited, commonly referred to as CSL, is a global biotechnology leader headquartered in Australia. Founded in 1916, the company has evolved significantly, establishing a strong presence in key operational regions including North America, Europe, and Asia-Pacific. Specialising in the development of innovative therapies for rare and serious diseases, CSL focuses on areas such as immunology, haematology, and respiratory health. The company is renowned for its core products, including immunoglobulins and clotting factors, which are distinguished by their high quality and efficacy. CSL's commitment to research and development has positioned it as a market leader, with notable achievements such as being consistently ranked among the top biopharmaceutical companies globally. With a rich history and a dedication to improving patient outcomes, CSL continues to set benchmarks in the biotechnology industry.
How does Csl's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Csl's score of 29 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, CSL Limited reported total carbon emissions of approximately 336,000,000 kg CO2e, comprising 113,000,000 kg CO2e from Scope 1 and 223,000,000 kg CO2e from Scope 2 emissions. This marks a reduction from 347,000,000 kg CO2e in 2022, indicating a commitment to lowering their carbon footprint. CSL has disclosed emissions data for Scope 1, 2, and 3, with Scope 3 emissions reaching approximately 2,284,000,000 kg CO2e in 2021, highlighting the significant impact of their supply chain and product lifecycle. The company has set near-term reduction targets, although it has not committed to a net-zero target as of now. CSL operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is headquartered in Australia. Their ongoing efforts reflect a commitment to sustainability and reducing greenhouse gas emissions, aligning with industry standards for climate action.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|
Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Csl is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.